checkAd

     334  0 Kommentare Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico - Seite 2

    For further information on Apricus, visit http://www.apricusbio.com

    *Vitaros® is a registered trademark of NexMed International Limited.  Such trademark is registered in certain countries throughout the world and pending registration in the United States.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: references to potential Vitaros approvals and product launches by Apricus' commercial partners in additional countries and the timing thereof; and the potential for Apricus to receive future milestone and royalty revenue. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus' control, including, but not limited to: Apricus' ability to have its product Vitaros be approved by relevant regulatory authorities in additional countries; Apricus' dependence on its commercial partners to carry out the commercial launch of Vitaros in Mexico and other territories and the potential for delays in the timing of commercial launch; Apricus' ability to obtain and maintain intellectual property protection for the product; Apricus' ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; competition in the ED market and other markets in which Apricus and its partners operate; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

    Seite 2 von 3



    GlobeNewswire
    0 Follower
    Autor folgen
    Verfasst von GlobeNewswire
    Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico - Seite 2 Ferring Plans to Launch in Mexico and Argentina During the Second Quarter 2017 SAN DIEGO, Jan. 18, 2017 (GLOBE NEWSWIRE) - Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and …